Ann: Novogen completes acquisition of Trialial P, page-6

re: Ann: Novogen completes acquisition of Tri... Those NRT holders who will get MEIP shares should read this.

http://seekingalpha.com/article/1042901-3-small-cap-biopharmas-with-trade-catalysts-and-speculation-investment-potential?source=yahoo


Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma remarked;

We are very encouraged not only by the response rates reported to date, but also by the rapid appearance of the responses with the combination of Pracinostat and Azacitidine. These data are particularly compelling given that most patients in the study had treatment-related MDS and expressed high-risk cytogenetic abnormalities, both of which carry a poor prognosis. With these data in hand, combined with the capital raise we announced yesterday [11/5/12], we expect to be in a position to rapidly advance to the next stage of development and initiate a randomized Phase II trial of Pracinostat in combination with Azacitidine in patients with MDS by the second quarter of next year.

The American Society of Hematology Annual Meeting is sure to get MEI some coverage here, and potentially positive data could rally the stock significantly higher than its current price level. Therefore, I bought some shares of it as a catalyst trade.